ATE306939T1 - Mehrstufiger kaskade-erhöhungsimpfstoff - Google Patents

Mehrstufiger kaskade-erhöhungsimpfstoff

Info

Publication number
ATE306939T1
ATE306939T1 AT95925387T AT95925387T ATE306939T1 AT E306939 T1 ATE306939 T1 AT E306939T1 AT 95925387 T AT95925387 T AT 95925387T AT 95925387 T AT95925387 T AT 95925387T AT E306939 T1 ATE306939 T1 AT E306939T1
Authority
AT
Austria
Prior art keywords
antibodies
vaccine
cells
infectious agents
tumor cells
Prior art date
Application number
AT95925387T
Other languages
English (en)
Inventor
Hans J Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23021598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306939(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE306939T1 publication Critical patent/ATE306939T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT95925387T 1994-07-06 1995-07-06 Mehrstufiger kaskade-erhöhungsimpfstoff ATE306939T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/268,129 US5798100A (en) 1994-07-06 1994-07-06 Multi-stage cascade boosting vaccine
PCT/US1995/008222 WO1996001126A1 (en) 1994-07-06 1995-07-06 Multi-stage cascade boosting vaccine

Publications (1)

Publication Number Publication Date
ATE306939T1 true ATE306939T1 (de) 2005-11-15

Family

ID=23021598

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95925387T ATE306939T1 (de) 1994-07-06 1995-07-06 Mehrstufiger kaskade-erhöhungsimpfstoff

Country Status (9)

Country Link
US (3) US5798100A (de)
EP (1) EP0768894B1 (de)
JP (2) JP3769014B2 (de)
AT (1) ATE306939T1 (de)
AU (1) AU2953895A (de)
CA (2) CA2194166C (de)
DE (1) DE69534528T2 (de)
IL (3) IL114444A (de)
WO (1) WO1996001126A1 (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354587B1 (en) * 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
JP2000511403A (ja) 1996-03-20 2000-09-05 イムノメディクス，インコーポレイテッド 抗癌胎児抗原抗イディオタイプ抗体のヒト化と腫瘍ワクチンとしての使用及びターゲッティング用途のための使用
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
ATE421888T1 (de) * 1997-08-13 2009-02-15 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CZ302801B6 (cs) 1999-01-13 2011-11-16 Igeneon Krebs-Immuntherapie Forschungs Und Entwicklungs-Ag Použití protilátky namírené proti antigenu bunecné membrány Ep-CAM pro výrobu farmaceutického prostredku
US7737258B2 (en) * 2000-10-18 2010-06-15 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7740845B2 (en) 2000-10-18 2010-06-22 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7666424B2 (en) * 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US8414892B2 (en) * 2000-10-18 2013-04-09 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US8501471B2 (en) 2000-10-18 2013-08-06 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8H9
US7244814B2 (en) * 2002-02-21 2007-07-17 University Of Medicine & Dentistry Of New Jersey Variant Tat proteins and methods for use thereof
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP4212921B2 (ja) * 2002-03-29 2009-01-21 独立行政法人科学技術振興機構 抗体を提示するタンパク質中空ナノ粒子を用いる治療薬剤およびタンパク質中空ナノ粒子
EP1572131B1 (de) 2002-10-08 2016-07-06 Immunomedics, Inc. Antikörper-therapie
GB0224442D0 (en) * 2002-10-21 2002-11-27 Molmed Spa A delivery system
HUE026914T2 (en) * 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
CN1902312B (zh) 2003-11-04 2011-02-23 株式会社载体研究所 制备导入了基因的树突细胞的方法
WO2005071092A1 (ja) 2004-01-22 2005-08-04 Dnavec Research Inc. サイトメガロウイルスエンハンサーおよびニワトリβ-アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖RNAウイルスベクターの製造方法
US20110064754A1 (en) * 2005-03-03 2011-03-17 Center For Molecular Medicine And Immunology Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8491914B2 (en) * 2004-02-13 2013-07-23 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for delivery of interference RNA
US8435539B2 (en) * 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8562988B2 (en) * 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US20110020273A1 (en) * 2005-04-06 2011-01-27 Ibc Pharmaceuticals, Inc. Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
DE102004054326B4 (de) * 2004-11-10 2007-01-11 FICO CABLES S.A. Technological Centre Pujol & Tarragó Vorrichtung zur Einstellung der Vorspannung eine Zugelements
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
EP2674440B1 (de) 2005-12-16 2019-07-03 IBC Pharmaceuticals, Inc. Polyvalente bioaktive anordnungen auf immunglobulinbasis
EP1983048A4 (de) 2006-01-17 2009-04-22 Dnavec Corp Neues proteinexpressionssystem
US8575319B2 (en) * 2006-03-10 2013-11-05 The Regents Of The University Of California Cleavable vaccine compositions and uses thereof and methods of making and using the same
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2048232A4 (de) 2006-07-13 2010-10-13 Dnavec Corp Nichtreplizierender paramyxoviridae-virusvektor
EP2121008A4 (de) * 2007-03-22 2010-03-31 Sloan Kettering Inst Cancer Verwendung des monoklonalen antikörpers 8h9
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20100203027A1 (en) 2007-04-27 2010-08-12 Kyushu Univeristy National University Viral vector for gene therapy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN102186499B (zh) * 2008-08-20 2015-05-20 Ibc医药公司 用于癌症治疗的对接和锁定(dnl)疫苗
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP3243527B1 (de) 2009-02-13 2019-06-05 Immunomedics, Inc. Immunkonjugate mit einem intrazellulär spaltbaren linker
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2506881B1 (de) 2009-12-02 2024-03-06 Immunomedics, Inc. Kombination aus radioimmuntherapie und antikörper-arznei-konjugaten für verbesserte krebstherapie
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
EP2747781B1 (de) 2011-08-23 2017-11-15 Roche Glycart AG Bispezifische antikörper spezifisch für t-zell-aktivierende antigene und ein tumorantigen sowie verwendungsverfahren
WO2014028560A2 (en) 2012-08-14 2014-02-20 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
AU2013360335B2 (en) 2012-12-13 2017-12-07 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
EP4282419A1 (de) 2012-12-20 2023-11-29 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
WO2014131712A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
EP3160504B1 (de) 2014-06-24 2020-09-16 Immunomedics, Inc. Antihistontherapie für vaskuläre nekrose bei schwerer glomerulonephritis
RS65573B1 (sr) 2014-08-04 2024-06-28 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
SI3204018T1 (sl) 2014-10-07 2021-11-30 Immunomedics, Inc. Neoadjuvantna uporaba konjugatov protitelo-zdravilo
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
EP3221356B1 (de) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T-zellen-aktivierende bispezifische antigenbindungsmoleküle gegen folr1 und cd3
US9797907B2 (en) 2015-04-22 2017-10-24 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
AU2016281622C1 (en) 2015-06-25 2021-11-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
WO2018129270A1 (en) * 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
EP3740198A4 (de) 2018-01-18 2023-08-09 Fred Hutchinson Cancer Center Veränderung von entzündungszuständen von immunzellen in vivo durch modulation von zellaktivierungszuständen
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
AU2021374590A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
JP2024500847A (ja) * 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818709A (en) * 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US5614610A (en) * 1984-12-21 1997-03-25 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
SG46445A1 (en) * 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
IL101147A (en) * 1991-03-07 2004-06-20 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras
US5932448A (en) * 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993019163A1 (en) * 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Chimeric receptor genes and cells transformed therewith
AU5097393A (en) * 1992-08-31 1994-03-29 Jenner Technologies Stimulation of an antitumor t-cell response using anti-idiotypic antibodies
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies

Also Published As

Publication number Publication date
CA2448831A1 (en) 2005-05-25
DE69534528T2 (de) 2006-07-13
JPH10503758A (ja) 1998-04-07
US5798100A (en) 1998-08-25
IL114444A0 (en) 1995-11-27
WO1996001126A1 (en) 1996-01-18
JP2000154153A (ja) 2000-06-06
CA2194166A1 (en) 1996-01-18
DE69534528D1 (de) 2006-03-02
EP0768894B1 (de) 2005-10-19
AU2953895A (en) 1996-01-25
JP3769014B2 (ja) 2006-04-19
EP0768894A1 (de) 1997-04-23
IL132468A0 (en) 2001-03-19
IL132468A (en) 2004-12-15
CA2194166C (en) 2003-11-25
US6132718A (en) 2000-10-17
IL114444A (en) 2000-02-17
US6926893B1 (en) 2005-08-09

Similar Documents

Publication Publication Date Title
DE69534528D1 (de) Mehrstufiger kaskade-erhöhungsimpfstoff
NO944475D0 (no) Kombinerte vaksiner omfattende Hepatit B overflateantigen og andre antigener
ES2184769T3 (es) Metodos y composiciones para microencapsulacion de antigenos para utilizar como vacunas.
LV12085A (lv) Dendritiskas sunas stimulejosais faktors
DK318481A (da) Syntetisk peptid specifik antigenisk determinant og fremgangsmaade til fremstilling af antigene meneraler deraf
ATE326479T1 (de) Varianten von antigenen des menschlichen papillomvirus
AU6054398A (en) Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
TR200001253T2 (tr) Tümöre özel antijenler
PT800578E (pt) Sequencias do anticorpo 3h1 anti-idiotipico monoclonal recombinante associado ao antigenio carcioembrionario humano
DK0527760T3 (da) Fremgangsmåder og præparater til vaccination mod HIV
ATE303160T1 (de) Impfstoff gegen prostatakrebs
DE58904760D1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.
EA199900069A1 (ru) Вакцинная композиция против малярии
DK98187A (da) Monoklonale antistoffer og antigen for human ikke-smaacellet lungecarcinoma og visse andre typer human carcinoma
DK0584715T3 (da) Fremgangsmåde til isolering og dyrkning af transformerede celler og anvendelse af disse til fremstilling af antistoffer ret
DK0541692T3 (da) Herpes simplex virus VP-16-vacciner
DK7891A (da) Anti-virus, anti-idiotype-antistof til induktion af immulogisk respons
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
EP2057999A3 (de) Verwendung von immunokonjugaten zur erhöhung der effektivität von mehrstufigen kaskaden-impfstoffen
SE9604581D0 (sv) An agent against cancer and virus infections
EP0690724A4 (de) Chlamydia impfstoff und verfahren
DK1021196T3 (da) Anvendelse af en kemisk stabiliseret chloritoplösning til inhibering af en antigenspecifik immunreaktion
IT8026986A0 (it) Antigene di prostata umana purificato e procedimento per preparare anticorpi correlati a tale antigene.
ES2180052T3 (es) Anticuerpos especificos del cancer de prostata para inmunodeteccion e inmunoterapia.
DE59710330D1 (de) Hybridzelle und deren Verwendung zur Herstellung eines Arzneimittels zur Induktion einer Tumorimmunität

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties